CollPlant Biotechnologies' Q3 revenue rises on rhCollagen sales, cuts workforce

Collplant Biotechnologies

26/11/2025 12:40

Overview

CollPlant Q3 2025 revenue increased significantly due to higher rhCollagen product sales

Company announces 25% workforce reduction to extend cash runway

CollPlant expands North American distribution through new U.S. logistics partnership

Outlook

CollPlant expects North American logistics center to be operational this quarter

Company plans to prioritize collaboration with AbbVie in 2026

CollPlant seeks strategic partner for regenerative breast implant development

Result Drivers

RH COLLAGEN SALES - Increased sales of rhCollagen products contributed to revenue growth

ABBVIE MILESTONE PAYMENT - $2 mln milestone payment from AbbVie boosted revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
9M Revenue
$2.30 mln
9M Adjusted EPS
-$0.58
9M EPS
-$0.69
9M Adjusted Net Income
-$7 mln
9M Net Income
-$8.30 mln
9M Operating Expenses
$10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Collplant Biotechnologies Ltd is $11.50, about 80.5% above its November 25 closing price of $2.24

Press Release: ID:nPn9sb26Va

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)